Dermata Therapeutics Shares Halted On Circuit Breaker To The Downside, Stock Now Up 139.2%
$DRMA
Biotechnology: Pharmaceutical Preparations
Health Care
Dermata Therapeutics Shares Halted On Circuit Breaker To The Downside, Stock Now Up 139.2%
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 9/21/2021 | $14.00 | Buy | Brookline Capital |
| 9/14/2021 | $9.00 | Buy | Maxim Group |
4 - Dermata Therapeutics, Inc. (0001853816) (Issuer)
4 - Dermata Therapeutics, Inc. (0001853816) (Issuer)
4 - Dermata Therapeutics, Inc. (0001853816) (Issuer)
SC 13G/A - Dermata Therapeutics, Inc. (0001853816) (Subject)
SC 13G - Dermata Therapeutics, Inc. (0001853816) (Subject)
SC 13G - Dermata Therapeutics, Inc. (0001853816) (Subject)
10-Q - Dermata Therapeutics, Inc. (0001853816) (Filer)
D - Dermata Therapeutics, Inc. (0001853816) (Filer)
EFFECT - Dermata Therapeutics, Inc. (0001853816) (Filer)
Brookline Capital initiated coverage of Dermata Therapeutics with a rating of Buy and set a new price target of $14.00
Maxim Group initiated coverage of Dermata Therapeutics with a rating of Buy and set a new price target of $9.00
SAN DIEGO, CA / ACCESSWIRE / January 13, 2022 / Dermata Therapeutics, Inc. (NASDAQ:DRMA) ("Dermata," or the "Company"), a clinical-stage biotechnology company focused on the treatment of medical and aesthetic skin conditions, today announced the appointment of Brittany Bradrick to its Board of Directors and its Audit Committee."I am excited to welcome Brittany to our Board of Directors," commented Gerry Proehl, Dermata's Chief Executive Officer, President, and Chairman. "Brittany brings an immense amount of industry expertise to Dermata and has an accomplished background with over 25 years' experience in finance, strategy, and corporate development for life science companies, with both opera
SAN DIEGO, CA / ACCESSWIRE / September 1, 2021 / Dermata Therapeutics, Inc. ("Dermata," or the "Company") (NASDAQ:DRMA)(NASDAQ:DRMAW), a clinical-stage biopharmaceutical company focused on the development of novel dermatology therapies, today announced the appointment of Kyri Van Hoose as Senior Vice President, Chief Financial Officer. Ms. Van Hoose is a strategic and operational finance leader with over 20 years of experience, including more than 15 years in the life sciences industry. Ms. Van Hoose is replacing Thomas Insley, who is retiring as the Company's full time CFO after 6 years, but will continue to work with the Company as a financial consultant."I am very excited to welcome Kyri
- End of Phase 2 meeting with FDA for DMT310 for moderate-to-severe acne expected in 2Q 2023 -- Initiation of DMT310 Phase 3 clinical trial program in moderate-to-severe acne patients expected in 2H 2023 -- DMT410 partnering discussions ongoing -SAN DIEGO, CA / ACCESSWIRE / February 21, 2023 / Dermata Therapeutics, Inc. (NASDAQ:DRMA, DRMAW))) ("Dermata," or the "Company"), a clinical-stage biotechnology company focusing on the treatment of medical and aesthetic skin conditions, today highlighted recent corporate progress, and reported financial results for the year ended December 31, 2022."We are very excited for what Dermata has planned for 2023 for both our DMT310 and DMT410 programs," sai
- DMT310 Phase 2 topline results in moderate-to-severe rosacea anticipated in December 2022 -- Initiation of DMT310 Phase 3 for moderate-to-severe acne expected in 1H 2023 -SAN DIEGO, CA / ACCESSWIRE / November 10, 2022 / Dermata Therapeutics, Inc. (NASDAQ:DRMA, DRMAW))) ("Dermata," or the "Company"), a clinical-stage biopharmaceutical company focusing on the treatment of medical and aesthetic skin conditions, today highlighted recent corporate progress, and reported financial results for the quarter ended September 30, 2022."I am thrilled with all that Dermata has accomplished so far this year and plan to continue the momentum as we near the announcement of our DMT310 Phase 2 topline result
- Dermata nears completion of enrollment in its DMT310 Phase 3 Spongilla Treatment of Acne Research (STAR-1) clinical trial -- Dermata continues discussions with potential botulinum toxin partners for DMT410 -- Raised $5.1 million in gross proceeds from financings completed in 3Q 2024 - SAN DIEGO, CA / ACCESSWIRE / November 13, 2024 / Dermata Therapeutics, Inc. (NASDAQ:DRMA, DRMAW)) ("Dermata," or the "Company"), a late-stage biotechnology company focused on the treatment of medical and aesthetic skin diseases and conditions, today highlighted recent corporate progress and reported financial results for the third quarter ended September 30, 2024."The third quarter was a busy time for our tea
SAN DIEGO, Nov. 11, 2024 (GLOBE NEWSWIRE) -- Dermata Therapeutics, Inc. (NASDAQ:DRMA, DRMAW)) ("Dermata" or the "Company"), a late-stage biotechnology company focused on the treatment of medical and aesthetics skin diseases and conditions, today announced that Gerry Proehl, Chairman, President, and Chief Executive Officer, will present live at the Life Sciences Investor Forum hosted by VirtualInvestorConferences.com, on Thursday, November 14, 2024 at 12:00 PM ET. Date: November 14, 2024 Time: 12:00pm – 12:30pm ET Link: https://bit.ly/3NuUDa4Available for 1x1 meetings: November 15 and 18, 2024 This will be a live, interactive online event where investors are invited to ask the Company que
SAN DIEGO, CA / ACCESSWIRE / October 8, 2024 / Dermata Therapeutics, Inc. (NASDAQ:DRMA)(NASDAQ:DRMAW) ("Dermata" or the "Company"), a late-stage biotechnology company focusing on the treatment of medical and aesthetic skin diseases and conditions, today announced that the Company's CEO, Gerry Proehl, will present at the 2024 Maxim Healthcare Virtual Summit, presented by Maxim Group LLC, on Tuesday, October 15, 2024, at 3:30PM ET.Maxim Senior Analysts will host a wide range of biotechnology, diagnostic, medical device, and healthcare information technology companies in a series of presentations and interactive discussions with CEOs and key management. They also plan to host several topical in
Dermata Therapeutics, Inc. (NASDAQ:DRMA) shares are trading north of 105% at last check Wednesday, and experiencing several trading halts. Here’s what you need to know. What Happened: Last week, the company announced it has enrolled 50% of patients in its pivotal Phase 3 STAR-1 clinical trial for a once-weekly topical acne treatment. This milestone is crucial as the company aims to release topline results in the first quarter of 2025. The treatment, DMT310, would be the first once-weekly topical product approved for treating moderate-to-severe acne if successful. Currently, 30 million patients seek treatment annually. The Phase 3 program includes two trials evaluating the ef
Shares of General Dynamics Corporation (NYSE:GD) fell sharply during Wednesday's session after the company reported worse-than-expected second-quarter EPS results. Revenue for the quarter increased 18% year-over-year to $11.976 billion, beating the consensus of $11.438 billion. EPS of $3.26 (up 20.7% YoY) missed the consensus of $3.29, according to data from Benzinga Pro. General Dynamics shares declined 5.2% to $279.26 on Wednesday. Here are some other stocks moving in today’s mid-day session. Gainers NuZee, Inc. (NASDAQ:NUZE) jumped 192% to $3.01. Dermata Therapeutics, Inc. (NASDAQ:DRMA) rose 142.4% to $3.0799 after falling over 22% on Tuesday. Selina Hospitality PLC